0.32  0 (0%)		11-15 16:00
Open: 0.3242 High: 0.33 Volume: 1,299,739		Pre. Close: 0.32 Low: 0.32 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.38	1-year :	0.45
Resists	First :	0.33	Second :	0.38
Pivot price	0.32
Supports	First :	0.31	Second :	0.31
MAs	MA(5) :	0.32	MA(20) :	0.32
	MA(100) :	0.29	MA(250) :	0.45
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	41.1	D(3) :	52.4
RSI	RSI(14): 52.2
52-week	High :	0.97	Low :	0.16

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MITO ] has closed above bottom band by 38.7%. Bollinger Bands are 74.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 65 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.33 - 0.33	0.33 - 0.33
Low:	0.32 - 0.32	0.32 - 0.32
Close:	0.32 - 0.32	0.32 - 0.32

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Wed, 16 Nov 2022
Stealth BioTherapeutics Corp Announces Completion of Merger - PR Newswire

Tue, 01 Nov 2022
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of ... - PR Newswire

Mon, 01 Aug 2022
Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction - PR Newswire

Mon, 01 Aug 2022
Stealth BioTherapeutics Enters Going Private Agreement - Yahoo Finance

Tue, 31 May 2022
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for ... - PR Newswire

Mon, 23 May 2022
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at ... - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	74 (M)
Shares Float	24 (M)
Held by Insiders	0.1 (%)
Held by Institutions	8.4 (%)
Shares Short	273 (K)
Shares Short P.Month	247 (K)

EPS	-0.93
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.76
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-67.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.63
Qtrly Earnings Growth	0 %
Operating Cash Flow	-45 (M)
Levered Free Cash Flow	-27 (M)

PE Ratio	-0.35
PEG Ratio	0.1
Price to Book value	-0.43
Price to Sales	0
Price to Cash Flow	-0.53

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.